30
Participants
Start Date
February 1, 2024
Primary Completion Date
February 1, 2026
Study Completion Date
February 1, 2027
Cadonilimab (AK104) combined with chemotherapy and bevacizumab
"Participants receive Cadonilimab PLUS chemotherapy and bevacizumab of each 21-day cycle.~Treatment period (4-8 cycles):~* Cadonilimab: 10mg/kg, intravenous infusion, D1, Q3W;~* CapeOx chemotherapy regimen Q3W+ bevacizumab, Q3W:~oxaliplatin: 130 mg/m2 intravenous infusion, D1, Q3W; capecitabine: 850 mg/m2 orally, D1-14, Q3W, twice daily; bevacizumab injection: 7.5mg/kg, IV, D1, Q3W. Maintenance treatment period:~* Cadonilimab: 10mg/kg, administered D1, Q3W;~* capecitabine: 1000 mg/m2 orally, D1-14, Q3W, twice daily;~* bevacizumab injection: 7.5mg/kg, IV, D1, Q3W."
RECRUITING
Shengjing Hospital of China Medical University, Shenyang
Caigang Liu
OTHER